Sulzer's INRange aims to cut heart valve complications
This article was originally published in Clinica
Sulzer Medica's cardiac surgery subsidiary, Sulzer Carbomedics, has begun clinical trials of INRange, a monitored heart valve service that measures the effects on patients of the anticoagulant drugs they take. The trials are designed to demonstrate that mechanical heart valve patients taking oral anticoagulants can reduce the complications associated with warfarin therapy by staying within the prescribed therapeutic range with the help of self-testing and telephone monitoring.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.